Thursday, March 26, 2026
Home Tags Alembic Pharmaceuticals

Tag: Alembic Pharmaceuticals

Alembic Pharmaceuticals and Amlan International launch MinerTox-Z and MinerTox-A
Brands in Conversation

Alembic Pharmaceuticals and Amlan International launch MinerTox-Z and MinerTox-A

Author -
0
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg
Brands in Conversation

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets

Passionate in Marketing -
0
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Extended-Release Tablets.
Brands in Conversation

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbamazepine Extended-Release Tablets.

Author -
0
Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen U.S. footprint
Brands in Conversation

Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen U.S. footprint

Author -
0
Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg
Brands in Conversation

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg

Author -
0
Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg.
Brands in Conversation

Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg.

Passionate in Marketing -
0
Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 110 mg.
Brands in Conversation

Alembic Pharmaceuticals announces USFDA Tentative Approval for Ivosidenib Tablets 250 mg

Passionate in Marketing -
0
Alembic Pharmaceuticals announces USFDA Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg
Brands in Conversation

Alembic Pharmaceuticals announces USFDA Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg

Passionate in Marketing -
0
Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
Brands in Conversation

Alembic Pharmaceuticals Receives 5 USFDA Product Approvals in Q1FY25

Passionate in Marketing -
0
Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
Brands in Conversation

Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) for its Oncology Formulation Facility at Panelav

Passionate in Marketing -
0
12Page 1 of 2

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

ABOUT US

Passionate in Marketing is promoted by i-miRa Knowledge Solutions, a company founded in 2010 to foster various business units dedicated to creating, disseminating, and managing knowledge-based products, services, and solutions. These offerings cater to corporate entities, startups, and academic institutions alike.

Contact : [email protected]

FOLLOW US

© 2026 | Passionate In Marketing |All Rights Reserved | Privacy Policy